Kh. Mayer et al., Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy, CLIN INF D, 28(6), 1999, pp. 1252-1259
Changes in human immunodeficiency virus (HIV) type 1 concentration and prot
ease genotype were evaluated in semen specimens from 22 HN-positive men bef
ore and 6 months after the addition of indinavir to dual nucleoside therapy
. Seminal HIV was detected by polymerase chain reaction analysis for DNA or
RNA for 59% of men before combination treatment and persisted at 6 months
for 31% of the men who initially had seminal HIV detected (P = .026). The m
aximum levels of cell-free RNA, cell-associated RNA, and proviral DNA in se
men before treatment and at 6 months were 400,000 and 10,000 copies/mL, 70,
000 and 27,000 copies/mL, and 80,000 and 3,000 copies/mL, respectively. Thr
ee of the four men with persistent seminal DNA had plasma viral loads of >1
0,000 copies/mL before treatment. One patient who became intolerant to indi
navir had seminal HN RNA detected by PCR analysis after 6 months. Although
none of the cultures of semen specimens from the four men with PCR analysis
-detectable seminal DNA after 6 months yielded HIV, indinavir resistance mu
tations were identified in a seminal leukocyte DNA specimen from one patien
t, and a second patient whose therapy was switched to saquinavir had differ
ent protease inhibitor resistance mutations in seminal and blood leukocyte
DNA specimens. HIV-1 protease inhibitor resistance mutants may emerge in th
e semen of patients receiving combination therapy.